Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission in the Absence of a Matched Identical Sibling: A Meta-Analysis

Acta Haematologica
Zhichao LiSiguo Hao

Abstract

The preferred type of postremission therapy (PRT) for intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate. Although allogeneic stem cell transplantation (alloSCT) is regarded as a curative strategy for AML, the efficacy of autologous stem cell transplantation (autoSCT) for patients without a matched sibling donor (MSD) has remained controversial. To compare survival outcomes after alloSCT versus autoSCT for patients with intermediate-risk AML in CR1, we performed a meta-analysis of 11 clinical studies. The outcomes included relapse-free survival (RFS), overall survival (OS), relapse rate (RR), and treatment-related mortality (TRM). Compared with autoSCT, alloSCT showed better RFS, OS, and RR benefits, but higher TRM. Subgroup analysis based on donor category (MSD and matched unrelated donor [MUD]) of alloSCT showed alloSCT from MSD rather than from MUD had better OS benefits compared to autoSCT. For fms-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) wild-type patients, alloSCT and autoSCT had comparable RFS and OS outcomes. Our results suggest that, in the absence of an available MSD, autoSCT remains a viable PRT alternative for intermediate-risk AML ...Continue Reading

References

Aug 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A S SteinS J Forman
Jun 23, 2006·Blood·Soheil MeshinchiTodd A Alonzo
Feb 22, 2007·Blood·Martin BornhäuserUNKNOWN AML SHG 96 study group
May 3, 2008·The New England Journal of Medicine·Richard F SchlenkUNKNOWN German-Austrian Acute Myeloid Leukemia Study Group
May 13, 2008·Haematologica·Dorle MessererUNKNOWN German AML Intergroup
Jul 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Norbert-Claude GorinUNKNOWN Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation
Sep 29, 2011·Blood·Edo VellengaUNKNOWN Swiss Group for Clinical Cancer Research Collaborative Group (SAKK)
Dec 27, 2011·The Lancet Oncology·Markus PfirrmannUNKNOWN Study Alliance Leukaemia (SAL)
Mar 16, 2012·The New England Journal of Medicine·Jay P PatelRoss L Levine
Feb 27, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettNigel Russell
May 2, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·James M ForanDaniel J Weisdorf
Sep 26, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Monique TerwijnGerrit J Schuurhuis
Jun 24, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Carlo MessinaMassimo Bernardi
Nov 25, 2014·Haematologica·Richard F Schlenk
Dec 3, 2014·Best Practice & Research. Clinical Haematology·Frederick R Appelbaum
Feb 1, 2015·Haematologica·Norbert-Claude GorinUNKNOWN Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Nov 26, 2015·Leukemia Research·María-Belén VidrialesUNKNOWN For PETHEMA Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group
Jan 31, 2016·Current Opinion in Hematology·Tsila ZuckermanJacob M Rowe
Sep 4, 2016·Journal of Hematology & Oncology·Francesco SaraceniUNKNOWN Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)
May 24, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Motonori MizutaniShingo Yano
Sep 30, 2017·American Journal of Hematology·Norbert-Claude GorinUNKNOWN Acute Leukemia Working Party of the EBMT
Jan 13, 2018·Current Opinion in Hematology·Chezi Ganzel, Jacob M Rowe

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.